Cargando…

Prevalence and predictors of complementary and alternative medicine/non-pharmacological interventions use for menopausal symptoms within the UK Collaborative Trial of Ovarian Cancer Screening

Objectives: The negative publicity about menopausal hormone therapy (MHT) has led to increased use of complementary and alternative medicines (CAM) and non-pharmacological interventions (NPI) for menopausal symptom relief. We report on the prevalence and predictors of CAM/NPI among UK postmenopausal...

Descripción completa

Detalles Bibliográficos
Autores principales: Gentry-Maharaj, A., Karpinskyj, C., Glazer, C., Burnell, M., Bailey, K., Apostolidou, S., Ryan, A., Lanceley, A., Fraser, L., Jacobs, I., Hunter, M. S., Menon, U.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448394/
https://www.ncbi.nlm.nih.gov/pubmed/28326899
http://dx.doi.org/10.1080/13697137.2017.1301919
_version_ 1783239550151163904
author Gentry-Maharaj, A.
Karpinskyj, C.
Glazer, C.
Burnell, M.
Bailey, K.
Apostolidou, S.
Ryan, A.
Lanceley, A.
Fraser, L.
Jacobs, I.
Hunter, M. S.
Menon, U.
author_facet Gentry-Maharaj, A.
Karpinskyj, C.
Glazer, C.
Burnell, M.
Bailey, K.
Apostolidou, S.
Ryan, A.
Lanceley, A.
Fraser, L.
Jacobs, I.
Hunter, M. S.
Menon, U.
author_sort Gentry-Maharaj, A.
collection PubMed
description Objectives: The negative publicity about menopausal hormone therapy (MHT) has led to increased use of complementary and alternative medicines (CAM) and non-pharmacological interventions (NPI) for menopausal symptom relief. We report on the prevalence and predictors of CAM/NPI among UK postmenopausal women. Method: Postmenopausal women aged 50–74 years were invited to participate in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). A total of 202 638 women were recruited and completed a baseline questionnaire. Of these, 136 020 were sent a postal follow-up-questionnaire between September 2006 and May 2009 which included ever-use of CAM/NPI for menopausal symptom relief. Both questionnaires included MHT use. Results: A total of 88 430 (65.0%) women returned a completed follow-up-questionnaire; 22 206 (25.1%) reported ever-use of one or more CAM/NPI. Highest use was reported for herbal therapies (43.8%; 9725/22 206), vitamins (42.6%; 9458/22 206), lifestyle approaches (32.1%; 7137/22 206) and phytoestrogens (21.6%; 4802/22 206). Older women reported less ever-use of herbal therapies, vitamins and phytoestrogens. Lifestyle approaches, aromatherapy/reflexology/acupuncture and homeopathy were similar across age groups. Higher education, Black ethnicity, MHT or previous oral contraceptive pill use were associated with higher CAM/NPI use. Women assessed as being less hopeful about their future were less likely to use CAM/NPI. Conclusion: One in four postmenopausal women reported ever-use of CAM therapies/NPI for menopausal symptom relief, with lower use reported by older women. Higher levels of education and previous MHT use were positive predictors of CAM/NPI use. UKCTOCS Trial registration: ISRCTN22488978
format Online
Article
Text
id pubmed-5448394
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-54483942017-06-13 Prevalence and predictors of complementary and alternative medicine/non-pharmacological interventions use for menopausal symptoms within the UK Collaborative Trial of Ovarian Cancer Screening Gentry-Maharaj, A. Karpinskyj, C. Glazer, C. Burnell, M. Bailey, K. Apostolidou, S. Ryan, A. Lanceley, A. Fraser, L. Jacobs, I. Hunter, M. S. Menon, U. Climacteric Original Article Objectives: The negative publicity about menopausal hormone therapy (MHT) has led to increased use of complementary and alternative medicines (CAM) and non-pharmacological interventions (NPI) for menopausal symptom relief. We report on the prevalence and predictors of CAM/NPI among UK postmenopausal women. Method: Postmenopausal women aged 50–74 years were invited to participate in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). A total of 202 638 women were recruited and completed a baseline questionnaire. Of these, 136 020 were sent a postal follow-up-questionnaire between September 2006 and May 2009 which included ever-use of CAM/NPI for menopausal symptom relief. Both questionnaires included MHT use. Results: A total of 88 430 (65.0%) women returned a completed follow-up-questionnaire; 22 206 (25.1%) reported ever-use of one or more CAM/NPI. Highest use was reported for herbal therapies (43.8%; 9725/22 206), vitamins (42.6%; 9458/22 206), lifestyle approaches (32.1%; 7137/22 206) and phytoestrogens (21.6%; 4802/22 206). Older women reported less ever-use of herbal therapies, vitamins and phytoestrogens. Lifestyle approaches, aromatherapy/reflexology/acupuncture and homeopathy were similar across age groups. Higher education, Black ethnicity, MHT or previous oral contraceptive pill use were associated with higher CAM/NPI use. Women assessed as being less hopeful about their future were less likely to use CAM/NPI. Conclusion: One in four postmenopausal women reported ever-use of CAM therapies/NPI for menopausal symptom relief, with lower use reported by older women. Higher levels of education and previous MHT use were positive predictors of CAM/NPI use. UKCTOCS Trial registration: ISRCTN22488978 Taylor & Francis 2017-05-04 2017-03-22 /pmc/articles/PMC5448394/ /pubmed/28326899 http://dx.doi.org/10.1080/13697137.2017.1301919 Text en © 2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/Licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/Licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Gentry-Maharaj, A.
Karpinskyj, C.
Glazer, C.
Burnell, M.
Bailey, K.
Apostolidou, S.
Ryan, A.
Lanceley, A.
Fraser, L.
Jacobs, I.
Hunter, M. S.
Menon, U.
Prevalence and predictors of complementary and alternative medicine/non-pharmacological interventions use for menopausal symptoms within the UK Collaborative Trial of Ovarian Cancer Screening
title Prevalence and predictors of complementary and alternative medicine/non-pharmacological interventions use for menopausal symptoms within the UK Collaborative Trial of Ovarian Cancer Screening
title_full Prevalence and predictors of complementary and alternative medicine/non-pharmacological interventions use for menopausal symptoms within the UK Collaborative Trial of Ovarian Cancer Screening
title_fullStr Prevalence and predictors of complementary and alternative medicine/non-pharmacological interventions use for menopausal symptoms within the UK Collaborative Trial of Ovarian Cancer Screening
title_full_unstemmed Prevalence and predictors of complementary and alternative medicine/non-pharmacological interventions use for menopausal symptoms within the UK Collaborative Trial of Ovarian Cancer Screening
title_short Prevalence and predictors of complementary and alternative medicine/non-pharmacological interventions use for menopausal symptoms within the UK Collaborative Trial of Ovarian Cancer Screening
title_sort prevalence and predictors of complementary and alternative medicine/non-pharmacological interventions use for menopausal symptoms within the uk collaborative trial of ovarian cancer screening
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448394/
https://www.ncbi.nlm.nih.gov/pubmed/28326899
http://dx.doi.org/10.1080/13697137.2017.1301919
work_keys_str_mv AT gentrymaharaja prevalenceandpredictorsofcomplementaryandalternativemedicinenonpharmacologicalinterventionsuseformenopausalsymptomswithintheukcollaborativetrialofovariancancerscreening
AT karpinskyjc prevalenceandpredictorsofcomplementaryandalternativemedicinenonpharmacologicalinterventionsuseformenopausalsymptomswithintheukcollaborativetrialofovariancancerscreening
AT glazerc prevalenceandpredictorsofcomplementaryandalternativemedicinenonpharmacologicalinterventionsuseformenopausalsymptomswithintheukcollaborativetrialofovariancancerscreening
AT burnellm prevalenceandpredictorsofcomplementaryandalternativemedicinenonpharmacologicalinterventionsuseformenopausalsymptomswithintheukcollaborativetrialofovariancancerscreening
AT baileyk prevalenceandpredictorsofcomplementaryandalternativemedicinenonpharmacologicalinterventionsuseformenopausalsymptomswithintheukcollaborativetrialofovariancancerscreening
AT apostolidous prevalenceandpredictorsofcomplementaryandalternativemedicinenonpharmacologicalinterventionsuseformenopausalsymptomswithintheukcollaborativetrialofovariancancerscreening
AT ryana prevalenceandpredictorsofcomplementaryandalternativemedicinenonpharmacologicalinterventionsuseformenopausalsymptomswithintheukcollaborativetrialofovariancancerscreening
AT lanceleya prevalenceandpredictorsofcomplementaryandalternativemedicinenonpharmacologicalinterventionsuseformenopausalsymptomswithintheukcollaborativetrialofovariancancerscreening
AT fraserl prevalenceandpredictorsofcomplementaryandalternativemedicinenonpharmacologicalinterventionsuseformenopausalsymptomswithintheukcollaborativetrialofovariancancerscreening
AT jacobsi prevalenceandpredictorsofcomplementaryandalternativemedicinenonpharmacologicalinterventionsuseformenopausalsymptomswithintheukcollaborativetrialofovariancancerscreening
AT hunterms prevalenceandpredictorsofcomplementaryandalternativemedicinenonpharmacologicalinterventionsuseformenopausalsymptomswithintheukcollaborativetrialofovariancancerscreening
AT menonu prevalenceandpredictorsofcomplementaryandalternativemedicinenonpharmacologicalinterventionsuseformenopausalsymptomswithintheukcollaborativetrialofovariancancerscreening